A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV Preexposure Prophylaxis open for volunteers to participate in research projects

ðŸ“Ģ āļĻāļđāļ™āļĒāđŒāļ§āļīāļˆāļąāļĒ HIV-NAT, āļĻāļđāļ™āļĒāđŒāļ§āļīāļˆāļąāļĒāđ‚āļĢāļ„āđ€āļ­āļ”āļŠāđŒāđāļĨāļ°āđ‚āļĢāļ„āļ•āļīāļ”āđ€āļŠāļ·āđ‰āļ­ āļŠāļ āļēāļāļēāļŠāļēāļ”āđ„āļ—āļĒ ðŸ’Šāļ‚āļ­āđ€āļŠāļīāļāđ€āļ‚āđ‰āļēāļĢāđˆāļ§āļĄāđ‚āļ„āļĢāļ‡āļāļēāļĢāļ§āļīāļˆāļąāļĒāļĒāļē PrEP āļŠāļ·āđˆāļ­āđ‚āļ„āļĢāļ‡āļāļēāļĢ “āļāļēāļĢāļĻāļķāļāļĐāļēāļ§āļīāļˆāļąāļĒāļ—āļēāļ‡āļ„āļĨāļīāļ™āļīāļāļĢāļ°āļĒāļ°āļ—āļĩāđˆ 3 āđāļšāļšāļŠāļļāđˆāļĄāđ‚āļ”āļĒāļ„āļ§āļšāļ„āļļāļĄāļ”āđ‰āļ§āļĒāļĒāļēāļ—āļĩāđˆāļ­āļ­āļāļĪāļ—āļ˜āļīāđŒāđāļšāļšāļ›āļāļ›āļīāļ”āļ—āļąāđ‰āļ‡ 2 āļāđˆāļēāļĒ āđ€āļžāļ·āđˆāļ­āļ›āļĢāļ°āđ€āļĄāļīāļ™āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļœāļĨāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļĒāļēāđ€āļ­āđ‡āļĄāđ€āļ„-8527 āđāļšāļšāļĢāļąāļšāļ›āļĢāļ°āļ—āļēāļ™āđ€āļ”āļ·āļ­āļ™āļĨāļ°āļ„āļĢāļąāđ‰āļ‡ āļŠāļģāļŦāļĢāļąāļšāļ›āđ‰āļ­āļ‡āļāļąāļ™āđ€āļŠāļ·āđ‰āļ­āđ€āļ­āļŠāđ„āļ­āļ§āļĩ-1…

C-FORWARD open for volunteers to participate in research projects

TB-SRN open for volunteers to participate in research projects

HIV-1 Subtype-Specific drug resistance in patients failing dolutegravir-based First-line, second-line or third-line regimens: multiregional study open for volunteers to participate in research projects